Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection
Authors:
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (20) , 126639
Abstract
No abstract availableKeywords
Funding Information
- Center for AIDS Research, Emory University
- Center for AIDS Research, University of Washington
- National Institutes of Health (1-R01-AI-132833)
This publication has 16 references indexed in Scilit:
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ TrialThe Journal of Infectious Diseases, 2018
- Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxilScientific Reports, 2018
- Efforts to Improve the Seasonal Influenza VaccineVaccines, 2018
- Inhibitors of Influenza A Virus PolymeraseACS Infectious Diseases, 2018
- The Next Wave of Influenza DrugsACS Infectious Diseases, 2017
- Pimodivir Treatment in Adult Volunteers Experimentally Inoculated with Live Influenza Virus: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled StudyAntiviral Therapy, 2017
- Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of InfluenzaACS Medicinal Chemistry Letters, 2017
- Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South AfricaAntiviral Research, 2009
- Novel Procedure for Modeling Ligand/Receptor Induced Fit EffectsJournal of Medicinal Chemistry, 2005
- Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concernThe Lancet, 2005